CRISPR,animals, and FDA oversight: Building a path to success |
| |
| Authors: | Laura R. Epstein Stella S. Lee Mayumi F. Miller Heather A. Lombardi |
| |
| Affiliation: | aOffice of the Director, Center for Veterinary Medicine, US Food and Drug Administration, Rockville, MD, 20855;bOffice of New Animal Drug Evaluation, Center for Veterinary Medicine, US Food and Drug Administration, Rockville, MD, 20855;cOffice of Research, Center for Veterinary Medicine, US Food and Drug Administration, Laurel, MD, 20708 |
| |
| Abstract: | Technological advances, such as genome editing and specifically CRISPR, offer exciting promise for the creation of products that address public health concerns, such as disease transmission and a sustainable food supply and enable production of human therapeutics, such as organs and tissues for xenotransplantation or recombinant human proteins to treat disease. The Food and Drug Administration recognizes the need for such innovative solutions and plays a key role in bringing safe and effective animal biotechnology products to the marketplace. In this article, we (the Food and Drug Administration/Center for Veterinary Medicine) describe the current state of the science, including advances in technology as well as scientific limitations and considerations for how researchers and commercial developers working to create intentional genomic alterations in animals can work within these limitations. We also describe our risk-based approach and how it strikes a balance between our regulatory responsibilities and the need to get innovative products to market efficiently. We continue to seek input from our stakeholders and hope to use this feedback to improve the transparency, predictability, and efficiency of our process. We think that working together, using appropriate science- and risk-based oversight, is the foundation to a successful path forward. |
| |
| Keywords: | CRISPR animals FDA CVM genome editing |
|
|
